All-cause and disease-related health care costs associated with recurrent venous thromboembolism

Summary

It was the objective of this study to quantify the risk of complications and the incremental health care costs associated with recurrent VTE events. Health care insurance claims from the Ingenix IMPACT database from 01/2004−09/2008 were analysed. Subjects aged ≥18 years on the date of first recurrent VTE diagnosis with ≥12 months of baseline observation prior to the index recurrent VTE were matched 1:1 with no-recurrent VTE patients based on propensity scores. The risk of developing post-thrombotic syndrome (PTS) and other disease-related diagnoses (thrombocytopenia, superficial venous thrombosis, venous ulcer, pulmonary hypertension, stasis dermatitis, and venous insufficiency) was compared between the recurrent and no-recurrent VTE groups for up to one year. All-cause and disease-related costs per patient per year (PPPY) were calculated. The recurrent VTE and no-recurrent VTE cohorts (8,001 subjects in each group) were matched with respect to age, gender, and comorbidities. The risk ratios (RRs) indicated that the risk of developing post-event complications was significantly higher for the recurrent VTE group compared to the no-recurrent VTE group (RR [95% CI]: PTS: 2.7 [2.4 − 2.9], p-value <0.01). Patients with recurrent VTE had significantly higher average PPPY all-cause costs compared to no-recurrent VTE patients ($86,744 versus $37,525, cost difference: $49,219 [€33,617]; 95% CI= 46,253−51,989). Corresponding disease-related health care costs PPPY were also significantly higher for the recurrent VTE group ($11,120 vs $1,262, cost difference: $9,858 [€6,733]; 95% CI= $9,081-$10,476). In conclusion, in this large matched-cohort study, recurrent VTE patients had significantly higher risk of complications and health care costs compared to no-recurrent VTE patients.

Note: Parts of this manuscript were presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting 2012, October 21–24, Hollywood, Florida and at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting 2013, May 18–22, New Orleans, LA, USA.

Keywords

Recurrent venous thromboembolism - complications - risks - costs

• References

• 1 Prandoni P, Lensing AW, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
• 2 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-662.
• 3 Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160: 769-774.
• 4 Heit JA, Mohr DN, Silverstein MD. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761-768.
• 5 MMWR Morb Mortal Wkly Rep. Venous thromboembolism in adult hospitalizations − United States, 2007-2009 Centers for Disease Control and Prevention (CDC) 2012; 61: 401-404.
• 6 Heit JA, Cohen AT, Anderson Jr FA. et al. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the U.S. Blood 2005; 106: 267a. Poster presented at: 47th Annual Meeting of the American Society of Hematology (ASH); December 10-14, 2005; Atlanta, GA.
• 7 The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Office of the Surgeon General (US). National Heart, Lung, and Blood Institute (US). Rockville (MD): Office of the Surgeon General (US); 2008.
• 8 Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?. J R Soc Med 1989; 82: 203-205.
• 9 Kopcke D, Harryman O, Benbow EW. et al. Mortality from pulmonary embolism is decreasing in hospital patients. J R Soc Med 2011; 104: 327-331.
• 10 Heit JA. The Epidemiology of Venous Thromboembolism in the Community: Implications for Prevention and Management. J Thromb Thrombolysis 2006; 21: 23-29.
• 11 Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: I22-30.
• 12 Labropoulos N, Spentzouris G, Sobreira ML. Clinical Significance of Recurrent Venous Thromboembolism. J Vasc Bras 2010; 9: 72-75.
• 13 Adcock DM. Recurrence of Thromboembolism: Determining Risk. Clin Hemost Rev 2005; 19: 1-5.
• 14 Brandjes DP, Büller HR, Heijboer H. et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759-762.
• 15 Kahn SR, Solymoss S, Lamping DL. et al. Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of life. J Gen Intern Med 2000; 15: 425-429.
• 16 Ginsberg JS, Turkstra F, Buller HR. et al. Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch Intern Med 2000; 160: 669-672.
• 17 Fanikos J, Piazza G, Zayaruzny M. et al. Long-Term Complications of Medical Patients with Hospital-Acquired Venous Thromboembolism. Thromb Haemost 2009; 102: 688-693.
• 18 Cohen AT, Agnelli G, Anderson FA. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
• 19 Mahan CE, Borrego ME, Woersching AL. et al. Venous thromboembolism: Annualised United States Models for Total, Hospital-Acquired and Preventable Costs Utilising Long-Term Attack Rates. Thromb Haemost 2012; 108: 291-302.
• 20 MacDougall DA, Feliu AL, Boccuzzi SJ. et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health-Syst Pharm 2006; 63: S5-S15.
• 21 Kirson NY, Birnbaum HG, Ivanova JI. et al. Excess Costs Associated with Patients with Chronic Thrombolic Pulmonary Hypertension in a US Privately Insured Population. Appl Health Econ Health Policy 2011; 9: 377-387
• 22 Bagelman SM, Hursting MJ, Aghababian RV. et al. Heparin-induced thrombocytopenia from venous thromboembolism treatment. J Intern Med 2005; 258: 563-572.
• 23 Kitchens CS. Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin-induced thrombocytopenia. Am J Hematol 2004; 76: 69-73.
• 24 Coon WW, Willis 3rd PW, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh Community Health Study. Circulation 1973; 48: 839-846.
• 25 Decousus H, Quéré I, Presles E. et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med 2010; 152: 218-224.
• 26 Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28: 370-372.
• 27 White JV, Ryjewski C. Chronic venous insufficiency. Perspect Vasc Surg Endovasc Ther 2005; 17: 319-327.
• 28 Pengo V, Lensing AW, Prins MH. et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-2264.
• 29 Vedantham S. Deep venous thrombosis: the opportunity at hand. Am J Roentgenol 2009; 193: 922-927.
• 30 Wolinsky CD, Waldrof H. Chronic venous disease. Med Clin North Am 2009; 93: 1333-1346.
• 31 Yamaki T, Nozaki M. Patterns of venous insufficiency after an acute deep vein thrombosis. J Am Coll Surg 2005; 201: 231-238.
• 32 Juhan CM, Alimi YS, Barthelemy PJ, Fabre DF, Riviere CS. Late results of iliofemoral venous thrombectomy. J Vasc Surg 1997; 25: 417-422.
• 33 Bank of Canada 10-year currency converter. Available at: http://www.bankofcanada.ca/rates/exchange/10-year-converter/ Accessed June 26, 2013.
• 34 Normand SLT, Landrum MB, Guadagnoli E. et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: A matched analysis using propensity scores. J Clin Epidemiol 2001; 54: 387-398.
• 35 Christiansen SC, Cannegieter SC, Koster T. et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293: 2352-2361.
• 36 Lefebvre P, Laliberté F, Nutescu EA. et al. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm 2012; 18: 363-374.
• 37 Van Dongen CJ, Prandoni P, Frulla M. et al. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 2005; 3: 939-942.
• 38 Pengo V, Lensing AW, Prins MH. et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-2264.
• 39 Bullano MF, Willey V, Wygant G. et al. Longitudinal Evaluation of Health Plan Cost per Venous Thromboembolism or Bleed Event in Patients With a Prior Venous Thromboembolism Event During Hospitalization. J Manag Care Pharm 2005; 11: 663-673.